Summary
Abbott Laboratories reported its first-quarter 2026 results, marked by significant strategic growth through the acquisition of Exact Sciences Corporation for approximately $20.6 billion. This transaction, largely funded by new debt, is expected to bolster Abbott's position in the cancer diagnostics market. Despite a challenging sales environment for Nutritional Products, overall net sales increased by 7.8% to $11.164 billion, driven by strong performance in Medical Devices and Established Pharmaceuticals, with a notable contribution from the new Cancer Diagnostics business. Financially, the company experienced a decrease in net earnings to $1.077 billion from $1.325 billion in the prior year, resulting in diluted EPS of $0.61, down from $0.76. This decline in profitability is largely attributable to increased operating costs, including those related to the Exact Sciences integration, and higher interest expenses associated with the acquisition financing. However, the company maintained a positive operating cash flow of $1.315 billion. Investors should note the significant increase in goodwill and intangible assets on the balance sheet due to the acquisition, alongside a substantial rise in long-term debt.
Financial Highlights
51 data points| Revenue | $11.16B |
| Cost of Revenue | $4.89B |
| Gross Profit | $6.27B |
| R&D Expenses | $767.00M |
| SG&A Expenses | $3.74B |
| Operating Expenses | $9.82B |
| Operating Income | $1.34B |
| Net Income | $1.08B |
| EPS (Basic) | $0.62 |
| EPS (Diluted) | $0.61 |
| Shares Outstanding (Basic) | 1.74B |
| Shares Outstanding (Diluted) | 1.75B |
Key Highlights
- 1Acquisition of Exact Sciences Corporation for approximately $20.6 billion completed on March 23, 2026, significantly expanding the Diagnostic Products segment, particularly in cancer diagnostics.
- 2Total net sales grew 7.8% year-over-year to $11.164 billion, driven by Medical Devices (+13.2%) and Established Pharmaceuticals (+13.2%), while Nutritional Products saw a decline (-6.0%).
- 3Net earnings decreased to $1.077 billion ($0.61 diluted EPS) from $1.325 billion ($0.76 diluted EPS) in the prior year, impacted by higher operating costs and interest expenses related to the Exact Sciences acquisition.
- 4Operating cash flow remained robust at $1.315 billion, although slightly down from $1.417 billion in the prior year.
- 5Long-term debt significantly increased by $19.742 billion to $29.638 billion, primarily to finance the Exact Sciences acquisition.
- 6Goodwill and Intangible Assets saw substantial increases on the balance sheet, reflecting the Exact Sciences acquisition ($11.4 billion in goodwill and $12.8 billion in acquired intangible assets).
- 7The company declared a quarterly dividend of $0.63 per share, an increase of 6.8% from the prior year's dividend.